Cargando…

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma

INTRODUCTION: Multiple myeloma (MM) is still an incurable plasma cell malignancy. The efficacy of immunotherapy on MM remains unsatisfactory, and the underlying molecular mechanisms still are not fully understood. METHODS: In this study, we delineated the dynamic features of immune cell in MM bone m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Junqiang, Sun, Hao, Gong, Lixin, Wei, Xiaojing, He, Yi, Yu, Zhen, Liu, Lanting, Yi, Shuhua, Sui, Weiwei, Xu, Yan, Deng, Shuhui, An, Gang, Yao, Zhi, Qiu, Lugui, Hao, Mu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748558/ https://www.ncbi.nlm.nih.gov/pubmed/36532059 http://dx.doi.org/10.3389/fimmu.2022.1077768

Ejemplares similares

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
por: Sun, Hao, et al.
Publicado: (2022)

Multiple myeloma–derived miR‐27b‐3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment
por: Wei, Xiaojing, et al.
Publicado: (2023)

Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
por: Liu, Lanting, et al.
Publicado: (2020)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma
por: Fang, Teng, et al.
Publicado: (2023)

P818: DNP73 PROMOTES DRUG RESISTANCE AND IMMUNE EVASION IN MULTIPLE MYELOMA BY MODULATING MYC/CD47 AXIS
por: Liu, Lanting, et al.
Publicado: (2023)

P838: EXOSOME MIRNAS PROFILING IN SERUM AND PROGNOSTIC EVALUATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Fang, Teng, et al.
Publicado: (2023)

P810: A NOVEL INDIRUBIN-3-MONOXIME DERIVATIVES FUNCTION AS DISRUPTORS OF PROTEOSTASIS VIA TARGETING TRIM28 IN MULTIPLE MYELOMA
por: Fang, Teng, et al.
Publicado: (2023)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
por: Yu, Zhen, et al.
Publicado: (2022)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
por: Hao, Mu, et al.
Publicado: (2011)

Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment
por: Xie, Zhenqing, et al.
Publicado: (2021)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
por: Xiong, Wenjie, et al.
Publicado: (2023)

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
por: Liu, Jiahui, et al.
Publicado: (2023)

Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment
por: Abdi, Jahangir, et al.
Publicado: (2014)

Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
por: Xu, Jingyu, et al.
Publicado: (2023)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

P803: CRIP1 INDUCES PIS RESISTANCE BY FORMING A COMPLEX WITH USP7/PA200 AND ENHANCING PROTEASOME ACTIVITY AND AUTOPHAGY IN MULTIPLE MYELOMA
por: Yu, Zhen, et al.
Publicado: (2023)

Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s
por: Zang, Meirong, et al.
Publicado: (2020)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
por: Lewinsky, Hadas, et al.
Publicado: (2021)

The association of HLA-C alleles with multiple myeloma in Chinese patients
por: Wang, Xiaojing, et al.
Publicado: (2018)

Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy
por: Wang, Tingting, et al.
Publicado: (2022)

Exosome-Mediated Immunosuppression in Tumor Microenvironments
por: Xie, Qi-Hui, et al.
Publicado: (2022)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

P910: DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?
por: Jingyu, X., et al.
Publicado: (2022)

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
por: Feng, Xiangling, et al.
Publicado: (2022)

Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma
por: Kuang, Chunmei, et al.
Publicado: (2023)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

P1162: FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA
por: Zou, Hesong, et al.
Publicado: (2023)

Gasdermin D Plays an Oncogenic Role in Glioma and Correlates to an Immunosuppressive Microenvironment
por: Li, Mengyuan, et al.
Publicado: (2023)

Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma
por: Shi, Lihui, et al.
Publicado: (2016)

Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
por: Visram, Alissa, et al.
Publicado: (2021)

Immunosuppressive Microenvironment in Neuroblastoma
por: Pistoia, Vito, et al.
Publicado: (2013)

S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study
por: Hao, Weiwei, et al.
Publicado: (2023)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_coq0abhjnfm37g7rclrbb93kvk